Forensic analysis of counterfeit medicine samples has enabled Interpol to track down the point of origin in China for the manufacturer of about 240,000 blister packs of imitation artesunate, an antimalarial treatment. The joint Interpol and World Health Organization effort, Operation Jupiter, led to 24,000 packs of the produced quantity being seized on the Yunnan, China-Myanmar border.
Mass spectrometry of tablets found traces of certain minerals and pollen, which allowed investigators to identify the exact region of China where the drugs were manufactured. Facundo Fernandez, an analytical chemist and assistant professor at Georgia Tech, USA, has pioneered new and faster techniques for analyzing suspect pharmaceutical samples (Marketletters passim). He told CNN that the technology is available to put a device in every pharmacy to check for counterfeit products.
A related project late last year involving Interpol and the WHO's International Medical Products Anti-Counterfeiting Taskforce (IMPACT) in Kenya and Tanzania, Operation Mamba, led to the seizure of 100 different types of fake drugs. Interpol reported that, in Tanzania, the secured products included antimalarial, cardiac, antifungal, multivitamin, hormone and skin medicines. 44 police cases were opened and several pharmacies and drug stores were closed down. In Uganda, 38 drug retail outlets have been put under investigation for operating without the necessary licenses and controls.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze